Journal of Clinical Oncology
Articles in this Issue
IPElife: Phase III, double-blind trial of <i>cannabis sativa</i> extract in pain management and quality of life in patients with metastatic lung cancer.
12061 Background: Pain and deterioration in quality of life (QoL) are among the most common and problematic symptoms reported by patients with late-stage...
Impact of HLA matching on clinical outcomes in a phase 2 trial of Bria-IMT plus anti PD1 in advanced breast cancer.
e13124 Background: Bria-IMT, an allogeneic whole-cell cancer vaccine (SV-BR-1-GM), was administered w/ an anti PD1 checkpoint inhibitor (CPI) to evaluate...
Demographic and clinical disparities in rectal cancer survival: A retrospective cohort analysis using Surveillance, Epidemiology, and End Results (SEER) data (2014–2020).
e15616 Background: Rectal cancer is a significant global health concern with survival rates varying by stage at diagnosis, age, sex, and race/ethnicity. T...
Cost-effectiveness of a two-protein panel PMS2/MSH6 for detecting mismatch repair deficiency in endometrial cancer: A single institution study.
e17613 Background: Several societies have advocated for universal Lynch syndrome screening in endometrial cancer (EC). Mismatch repair proteins (MMR) are...
Combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer: A systematic review and meta-analysis.
e15516 Background: Approximately 4-5% of patients with metastatic colorectal cancer (mCRC) exhibit tumors with mismatch repair deficiency (dMMR) or high m...
Incidence and mortality of endometrial cancer in Appalachian eastern Kentucky.
e13809 Background: Endometrial cancer significantly impacts the Appalachian population compared to the overall United States population. Evidence supports...
Effect of carotuximab (ENV105)-mediated CD105 blockade on osimertinib sensitivity in EGFR-mutant non-small cell lung cancer persister cells.
e20009 Background: Osimertinib resistance in patients with EGFR-driven non-small cell lung cancer (NSCLC) contributes to mortality. Targeting bypass alter...
Early phase I study of non-viral CD19/CD22/BCMA tri-targeting JL-Lightning-CAR-T in relapsed/refractory B-cell non-Hodgkin's lymphoma.
e14521 Background: Research indicates that CAR-T cell proliferation and persistence correlates with clinical responses, particularly in hematological mali...
Real-world outcomes in a Latin American setting with first-line osimertinib in EGFR-mutated NSCLC.
e20682 Background: In non-small cell lung cancer (NSCLC), mutations in the epidermal growth factor receptor (EGFR) represent a significant therapeutic tar...
Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).
6501 Background: ASC, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket, recently received FDA Accelerated Approval for newly...
Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity.
2587 Background: A small molecule was identified that stabilizes the trimerization of the glucacorticoid-induced tumor necrosis factor receptor (GITR) lig...
Comprehensive molecular analysis of phase II trial of nivolumab in patients with recurrent or metastatic carcinosarcomas.
11542 Background: We conducted a single-center, prospective, phase II trial to evaluate the efficacy and safety of nivolumab, an anti-PD-1 immune checkpoi...
Patient records to timelines: A LLM-based approach for summarizing oncology patient history.
e13688 Background: In the era of precision oncology, timely treatment decisions demand a clear view of a patient’s clinical history, yet records are often...
Analysis of ASCO clinical guidelines authorship and institutional representation using HemOnc.org.
e13577 Background: Evidence-based clinical practice guidelines (CPGs) are vital for safe and updated oncology care. ASCO produces CPGs across solid and bl...
Clinical outcomes for smokers with early-onset breast cancer: An analysis of the National Inpatient Sample.
e23358 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing g...
Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer.
1081 Background: The efficacy of sacituzumab govitecan (SG), a TROP2-directed antibody-drug conjugate (ADC), in hormone receptor-positive/HER2-negative (H...
Survival of malignant peripheral nerve sheath tumor of the trachea, mediastinum, and other respiratory organs: Analysis of SEER database.
e23550 Background: Malignant peripheral nerve sheath tumor (MPNST) is a rare form of sarcoma arising from Schwann cells with an incidence rate of about 1...
Machine learning-based prediction of cytokine release syndrome post CAR-T cell therapy.
e13622 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment of hematologic malignancies; however, severe toxicities l...
Evaluating the role of dietary interventions in reducing chemotherapy toxicities in cancer patients: A systematic review.
e13869 Background: Despite advancements in cancer treatment, chemotherapy remains an indispensable treatment modality. Chemotherapy drugs inadvertently ha...
Real-world validation of the risk estimation of tumor recurrence after transplant (RETREAT) score: Insights from UNOS data on hepatocellular carcinoma recurrence after liver transplant.
4117 Background: For over two decades, established criteria have guided the selection of liver transplantation (LT) candidates in hepatocellular carcinoma...
Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.
2011 Background: Radiation therapy forms the mainstay of management for patients with brain metastases. Published randomiz...
Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion–positive (NTRK+) solid tumors.
3112 Background: NTRK gene fusion is one of the most defined driving factors of carcinogenesis, which occurs in various adult tumor types. Zurlectrectinib...
Tumor-derived exosomes (TDEs) as communicators for cancer development and metastasis.
e13031 Background: Comprehensive targeting of cancer communication through inhibition of Tumor-derived exosomes (TDEs) secretion by tumor cells and blocki...
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.
TPS625 Background: Approximately 50% of newly diagnosed invasive breast cancers are stage 1, with the majority being ER/PR-positive, HER2-negative. Genomi...
Carcinoid heart disease and urinary 5-HIAA in patients with pancreatic neuroendocrine tumors.
e16350 Background: Neuroendocrine tumors (NETs) can cause carcinoid syndrome and carcinoid heart disease (CHD), leading to pulmonic or tricuspid fibrosis...